335 related articles for article (PubMed ID: 15982658)
1. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
Albert MA; Glynn RJ; Wolfert RL; Ridker PM
Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
[TBL] [Abstract][Full Text] [Related]
3. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Asztalos BF; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2005 May; 95(9):1025-32. PubMed ID: 15842965
[TBL] [Abstract][Full Text] [Related]
4. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
White HD; Simes J; Stewart RA; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A;
J Am Heart Assoc; 2013 Oct; 2(5):e000360. PubMed ID: 24152981
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
[TBL] [Abstract][Full Text] [Related]
7. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis.
Khuseyinova N; Imhof A; Rothenbacher D; Trischler G; Kuelb S; Scharnagl H; Maerz W; Brenner H; Koenig W
Atherosclerosis; 2005 Sep; 182(1):181-8. PubMed ID: 16115490
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
Koenig W; Twardella D; Brenner H; Rothenbacher D
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
[TBL] [Abstract][Full Text] [Related]
11. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.
Dohi T; Miyauchi K; Okazaki S; Yokoyama T; Ohkawa R; Nakamura K; Yanagisawa N; Tsuboi S; Ogita M; Yokoyama K; Kurata T; Yatomi Y; Daida H
Atherosclerosis; 2011 Dec; 219(2):907-12. PubMed ID: 22024276
[TBL] [Abstract][Full Text] [Related]
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
[TBL] [Abstract][Full Text] [Related]
14. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
16. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up.
Brilakis ES; McConnell JP; Lennon RJ; Elesber AA; Meyer JG; Berger PB
Eur Heart J; 2005 Jan; 26(2):137-44. PubMed ID: 15618069
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
May HT; Horne BD; Anderson JL; Wolfert RL; Muhlestein JB; Renlund DG; Clarke JL; Kolek MJ; Bair TL; Pearson RR; Sudhir K; Carlquist JF
Am Heart J; 2006 Nov; 152(5):997-1003. PubMed ID: 17070179
[TBL] [Abstract][Full Text] [Related]
18. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus.
Wootton PT; Stephens JW; Hurel SJ; Durand H; Cooper J; Ninio E; Humphries SE; Talmud PJ
Atherosclerosis; 2006 Nov; 189(1):149-56. PubMed ID: 16438975
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
20. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
